Video

Challenges in the Diagnosis of Neuroendocrine Tumors

For High-Definition, Click

When referred to academic centers, many patients who have been diagnosed with a neuroendocrine tumor (NET) have received a broad assortment of tests and assays. In general, Rodney F. Pommier, MD notes, the first task when seeing these patients is to narrow down the information based on clinical parameters.

To determine diagnosis patterns, Pommier analyzed 150 patients with abdominal carcinoids. Out of these patients, only 3.5% of patients were referred 3 months following their initial presentation. The remaining 96.5% of patients received a diagnosis on average 6.5 years after presentation and even up to 20 years in some cases. In general, these patients receive 35 different initial diagnoses.

This delay, Pommier feels, may be related to the fact that community physicians are not initially thinking about carcinoids as a potential diagnosis. This is due to a combination of the natural characteristics of the disease and a lack of general awareness.

Related Videos
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.